Validation of midbrain positron emission tomography measures for nigrostriatal neurons in macaques

Annals of Neurology

Volumn 74, Issue 4, 2013, Pages 602-610

  Brown, Christopher A ^a   Karimi, Morvarid K ^a   Tian, Linlin ^a   Flores, Hugh ^a   Su, Yi ^b   Tabbal, Samer D ^c   Loftin, Susan K ^a   Moerlein, Stephen M ^a,b   Perlmutter, Joel S ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY   (United States)

^c AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 2BETA METHOXY 3BETA 4 FLUOROPHENYLTROPANE C 11; 6 FLUORODOPA F 18; CARBON 11; DIHYDROTETRABENAZINE; DIHYDROTETRABENAZINE C 11; DOPAMINE; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BRAIN SIZE; CONTROLLED STUDY; CORPUS STRIATUM; CORRELATION ANALYSIS; DOPAMINE BRAIN LEVEL; MACACA; MALE; MESENCEPHALON; MOTOR DYSFUNCTION; NERVE CELL NECROSIS; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SUBSTANTIA NIGRA; VALIDATION STUDY;

ANIMALS; CARBON ISOTOPES; DISEASE MODELS, ANIMAL; FLUORODEOXYGLUCOSE F18; MACACA MULATTA; MAGNETIC RESONANCE IMAGING; MALE; MESENCEPHALON; MPTP POISONING; NEURONS; POSITRON-EMISSION TOMOGRAPHY; SUBSTANTIA NIGRA; TETRABENAZINE;

EID: 84890123415     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.23939     Document Type: Article

References (37)

1. Tabbal SD, Tian LL, Karimi MK, et al. Low nigrostriatal reserve for motor parkinsonism in nonhuman primates. Exp Neurol 2012; 237: 355-362.
2. The Parkinson Study Group. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004; 351: 2498-2508.
3. Whone AL, Watts RL, Stoessl AJ, et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol 2003; 54: 93-101.
4. Lang AE, Gill S, Patel NK, et al. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol 2006; 59: 459-466.
5. Ravina B, Eidelberg D, Ahlskog JE, et al. The role of radiotracer imaging in Parkinson disease. Neurology 2005; 64: 208-215.
6. Tian LL, Karimi MK, Loftin SK, et al. No differential regulation of dopamine transporter (DAT) and vesicular monoamine transporter 2 (VMAT2) binding in a primate model of Parkinson disease. PLoS One 2012; 7: e31439.
7. Karimi MK, Brown CA, Tian LL, et al. Validation of nigrostriatal positron emission tomography measures: critical limits. Ann Neurol 2013; 73: 390-396.
8. Martin WW, Perlmutter JS,. Assessment of fetal tissue transplantation in Parkinson's disease: does PET play a role? Neurology 1994; 44: 1777-1780.
9. Bohnen NI, Albin RL, Koeppe RA, et al. Positron emission tomography of monoaminergic vesicular binding in aging and Parkinson disease. J Cereb Blood Metab 2006; 26: 1198-1212.
10. Chen M-K, Kuwabara H, Zhou Y, et al. VMAT2 and dopamine neuron loss in a primate model of Parkinson's disease. J Neurochem 2008; 105: 78-90.
11. Masilamoni G, Votaw J, Howell L, et al. 18F-FECNT: validation as PET dopamine transporter ligand in parkinsonism. Exp Neurol 2010; 226: 265: 273.
12. 123I] beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease. Neurology 1996; 46: 231-237.
13. Koeppe RA, Frey KA, Vander Borght TM, et al. Kinetic evaluation of [11C]dihydrotetrabenazine by dynamic PET: measurement of vesicular monoamine transporter. J Cereb Blood Metab 1996; 16: 1288-1299.
14. Brownell A-L, Elmaleh DR, Metlzer PC, et al. Cocaine congeners as PET imaging probes for dopamine terminals. J Nucl Med 1996; 37: 1186-1192.
15. Tabbal SD, Mink JW, Antenor JA, et al. 1-Methyl-4-phenyl-1,2,3,6- tetrahydropyridine-induced acute transient dystonia in monkeys associated with low striatal dopamine. Neuroscience 2006; 141: 1281-1287.
16. Nishant K, Lee JJ, Perlmutter JS, Derdeyn CP,. Cervical carotid and circle of Willis arterial anatomy of macaque monkeys: a comparative anatomy study. Anat Rec 2009; 292: 976-984.
17. Perlmutter JS, Tempel LW, Black KJ, et al. MPTP induces dystonia and parkinsonism: clues to the pathophysiology of dystonia. Neurology 1997; 49: 1432-1438.
18. Tai Y-C, Ruangma A, Newport DF, et al. Performance evaluation of the microPET focus: a third-generation microPET scanner dedicated to animal imaging. J Nucl Med 2005; 46: 455-463.
19. Foster ER, Black KJ, Antenor J, et al. Motor asymmetry and substantia nigra volume are related to spatial delayed response performance in Parkinson disease. Brain Cogn 2008; 67: 1-10.
20. Rowland DJ, Garbow JR, Laforest R, Snyder AZ,. Registration of [18F]FDG microPET and small-animal MRI. Nucl Med Biol 2005; 32: 567-572.
21. Logan J,. Graphical analysis of PET data applied to reversible and irreversible tracers. Nucl Med Biol 2000; 27: 661-670.
22. Sossi V, Holden JE, Chan G, et al. Analysis of four dopaminergic tracers kinetics using two different tissue input function methods. J Cereb Blood Flow Metab 2000; 20: 653-660.
23. Patlak CS, Blasberg RG, Fenstermacher JD,. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab 1983; 3: 1-7.
24. Patlak CS, Blasberg RG,. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations. J Cereb Blood Flow Metab 1985; 5: 584-590.
25. Karimi MK, Carl JL, Loftin SK, Perlmutter JS,. Modified high-performance liquid chromatography with electrochemical detection method for plasma measurement of levodopa, 3-O-methyldopa, dopamine, carbidopa and 3,4-dihydroxyphenyl acetic acid. J Chromatogr B 2006; 836: 120-123.
26. Hersch SM, Yi H, Heilman CJ, et al. Subcellular localization and molecular topology of the dopamine transporter in the striatum and substantia nigra. J Comp Neurol 1997; 388: 211-227.
27. Nirenberg MJ, Chan J, Liu Y, et al. Ultrastructural localization of the vesicular monoamine transporter-2 in midbrain dopaminergic neurons: potential sites for somatodendritic storage and release of dopamine. J Neurosci 1996; 16: 4135-4145.
28. Nahmias C, Wahl L, Chirakal R, et al. A probe for intracerebral aromatic amino-acid decarboxylase activity: distribution and kinetics of [18F]6-fluoro-L-m-tyrosine in the human brain. Mov Disord 1995; 10: 298-304.
29. Barrio JR, Huang S-C, Yu D-C, et al. Radiofluorinated L-m-tyrosines: new in-vivo probes for central dopamine biochemistry. J Cereb Blood Metab 1996; 16: 667-678.
30. Brown WD, DeJesus OT, Pyzalski RW, et al. Localization of trapping of 6-[18F]fluoro-L-m-tyrosine, an aromatic L-amino acid decarboxylase tracer for PET. Synapse 1999; 34: 111-123.
31. Eberling JL, Bankiewicz KS, Jordan S, et al. PET studies of functional compensation in primate model of Parkinson's disease. Neuroreport 1997; 8: 2727-2733.
32. Dang LC, O'Neil JP, Jagust WJ,. Genetic effects on behavior are mediated by neurotransmitters and large-scale neural networks. Neuroimage 2012; 66: 203-214.
33. Michell AW, Lewis JG, Foltynie T, Barker RA,. Biomarkers and Parkinson's disease. Brain 2004; 127: 1693-1705.
34. Dorsey ER, Holloway RG, Ravina BM,. Biomarkers in Parkinson's disease. Expert Rev Neurother 2006; 6: 823-831.
35. Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004; 351: 2498-2508.
36. Meissner W, Prunier C, Guilloteau D, et al. Time-course of nigrostriatal degeneration in a progressive MPTP-lesioned macaque model of Parkinson's disease. Mol Neurobiol 2003; 28: 209-218.
37. Braak H, Ghebremedhin E, Rub U, et al. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res 2004; 318: 121-134.